At Arquer Diagnostics, we are at the forefront of a revolution in cancer diagnosis, helping transform how people are diagnosed and monitored with the disease.

In some cases, 90-95% of those undergoing invasive and often painful procedures are found to not have cancer. That is why there is a need for a fast, painless and highly accurate way to help clinicians decide who may have cancer and need further investigation and who doesn’t.

Using our breakthrough urinary biomarker technology, we have created a range of new generation tests for some of the most common cancers – bladder, endometrial, ovarian and prostate – which are backed by a rigorous and comprehensive clinical trials programme.

The simplicity of our patented technology is its biggest strength. Our tests are accurate, reliable, cost-effective, and can be used universally. We have strong advisory boards – every step we take is guided by clinicians, putting patient’s needs at the forefront of our decision-making. And our dedicated team has proved it can deliver across R&D, product development, clinical trial programmes and robust manufacturing through to distribution and marketing.